The subgroup analysis factors included cancer types (ALL vs. NHL), region (China vs. USA), age (adult ≥ 20 years old vs. child and young ≤ 30), T-cell origin (autologous vs. allologous), co-stimulation domain (4-1BB vs. CD28 vs. 4-1BB combined with CD28), vector (gammaretrovirus vs. lentivirus vs. retrovirus), lympho-depletion protocol (Cy vs. Cy + Flu), and dose (105–106/kg vs. 106/kg vs. 106–108/kg). This evidence concerns the gene CD28 and cancer.